SecBot SecBot
PRESS-RELEASE ·Filed Apr 7, 2026

EVAX

Evaxion
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

The strong durability and immunogenicity data support EVX-01's clinical promise; traders should position ahead of the H2 2026 three-year data readout, which could serve as a major value driver. Watch for potential partnership or licensing interest ahead of data disclosure.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.80
T+0 close · Apr 7, 2026 · via day close
Latest settled
−10.26%
T+60 · $3.41
Vs SPY
−23.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $3.80entry
  2. T+1 · 7mo ago +6.84%α +4.30% · $4.06
  3. T+5 · 7mo ago +8.95%α +3.62% · $4.14
  4. T+20 · 7mo ago +20.26%α +10.48% · $4.57
  5. T+60 · 5mo ago −10.26%α −23.53% · $3.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced the successful completion of the one-year extension of its phase 2 trial for its personalized cancer vaccine EVX-01, with three-year clinical efficacy data expected in the second half of 2026. The trial has already shown a 75% Objective Response Rate and high durability, with 92% of patients still responding at two years and no relapses observed.

Key Facts

  • Phase 2 trial extension completed; final three-year data expected in H2 2026
  • Objective Response Rate of 75% (12 of 16 patients) with 4 complete responses
  • 92% of patients maintained response at two-year follow-up; no relapses observed
  • EVX-01 induced immune response in 100% of patients; 81% of targeted neoantigens generated potent T-cell responses
  • Vaccine evaluated in advanced melanoma, combining EVX-01 with Keytruda® followed by monotherapy in year three

Financial Impact

Potential catalyst for value inflection pending 2026 data readout; current market cap of $31M reflects high risk/reward profile

market valuationclinical pipeline valueinvestor sentiment

Risk Factors

  • Clinical trial results remain early-stage with small sample size (n=16)
  • Future data may not maintain current efficacy or durability trends
  • High market expectations could lead to sell-off if 2026 data is merely incremental

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3269035

Track record

50 reports on EVAX

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026